Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics is supported by a commercially approved, differentiated autologous gene therapy in ZEVASKYN that addresses the large unmet need in RDEB, with published clinical data showing durable healing, strong efficacy, and safety. Its commercial case is strengthened by accelerating adoption metrics such as 1Q26 revenue of $8.7M, six QTCs active, 95% commercial coverage, and expectations for 7-10 QTCs at steady state with more than 10 treatments per month across the U.S., while management believes cash flow-positive status can be reached at an annualized run rate below $100M. Financially, the company also has meaningful optionality from partnered and pipeline assets, including up to 10% royalties and up to $30M in milestones from Ultragenyx, plus AAV ophthalmology programs and manufacturing expansion that could support roughly 20 slots and further scale over time.

Abeona Therapeutics is viewed negatively because its lead ZEVASKYN launch is already showing commercialization and manufacturing fragility, with 2Q revenue of $11.4M below the $13.4M/$12.1M expectations as one fewer treatment was billed due to low manufacturing yield and an out-of-spec product. The company also faces structural gene-therapy risks, including serious adverse events, immune and off-target effects, heightened regulatory scrutiny, and the complexity of producing cell and gene therapies to predefined specifications, all of which can slow adoption and increase costs. In addition, reimbursement resistance, orphan-drug exclusivity uncertainty, and the possibility of greater-than-anticipated financing needs create a difficult path to durable earnings and limit confidence in near-term execution.